Honokiol for early-stage lung cancer before surgery
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a natural compound called honokiol in people with early-stage non-small cell lung cancer who are scheduled for surgery. The goal is to see if honokiol can help shrink or control the tumor before it is removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have early-stage non-small cell lung cancer that can be removed with surgery.
- You are at least 18 years old.
- Your cancer can be measured on scans (RECIST criteria).
- Your blood counts and organ function meet certain minimum levels.
- You have not had other cancer treatments like chemotherapy or radiation in the last 2 weeks.
- You are willing to follow the study schedule and attend all visits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving a combination of two drugs (sintilimab and anlotinib) before surgery can help shrink non-small cell lung cancer tumors and improve outcomes. It is for people with stage IB to IIIB cancer that can be removed with surgery and who have not had treatment yet.
This study tests whether giving a combination of three medicines before surgery can help shrink tumors in people with stage 2 or 3 non-small cell lung cancer, potentially making surgery and recovery more effective. The medicines include an immunotherapy drug (tislelizumab), a targeted therapy (anlotinib), and a chemotherapy drug (nab-paclitaxel).
This trial tests an investigational drug called JSKN016 given before surgery to shrink non-small cell lung cancer tumors and improve outcomes. The goal is to see if this pre-treatment is safe and effective for patients with stage II-III disease that can be surgically removed.
This trial tests a combination of radiation therapy before surgery, followed by the immunotherapy drug tislelizumab and the targeted therapy drug anlotinib after surgery, for people with stage II to IIIA non-small cell lung cancer (NSCLC). The goal is to see if this approach can improve outcomes for patients whose tumors can be removed surgically.
This trial tests whether adding natural killer (NK) cell therapy to standard chemotherapy and a PD-1 inhibitor (a type of immunotherapy) before surgery can help shrink early-stage non-small cell lung cancer and improve outcomes. The goal is to see if this combination is safe and effective.
This trial is looking at whether using a sensitive blood test to find tiny bits of cancer left after surgery can help guide whether extra treatment is needed. The goal is to see if this approach is better than standard care for early-stage lung cancer patients.
Hear when a new Carcinoma, Non-Small-Cell Lung trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.